Enel Health®Atlas
Sign in
Enel Health®Atlas
Browse libraries

Not medical advice. The Atlas is not a substitute for a clinician who can examine you.

L. rhamnosus GG

LGG · The Most-Studied Probiotic Strain

Evidence grade 4 of 5, Strong. Read how the Atlas grades evidence.

80 human trials, about 300 studies, >20,000 participants. The written rationale for this grade is still being prepared.

FDA
GRAS; Culturelle
WADA
Not prohibited

Reference only. Not medical advice.

What can go wrong

Generally very safe in healthy children and adults, with a strong long-term safety record. The documented serious risk is rare bacteremia in vulnerable patients: a whole-genome-sequencing case report confirmed 0 SNPs between blood isolate and the ingested LGG capsule in a critically ill, multi-trauma patient with a central venous catheter, and Lactobacillus bloodstream infections carry meaningful mortality in immunocompromised populations. LGG is best avoided in people who are severely immunocompromised, critically ill, have short-gut or compromised intestinal-barrier integrity, or have central venous catheters, unless a clinician advises otherwise. Because pediatric, pregnancy, and immunocompromised use involve individual medical judgment, decisions in those situations should be made with a qualified healthcare provider rather than self-directed. Benefits are indication-specific, not a cure-all.

Lactobacillus rhamnosus GG, the "GG" honoring discoverers Sherwood Gorbach and Barry Goldin who isolated it at Tufts in 1983-1985, is the most extensively studied probiotic strain in the world and the strain inside the mass-market brand Culturelle. It carries spaCBA pili that bind human intestinal mucus, and its strongest, best-replicated benefit is preventing antibiotic-associated diarrhea, especially in children and during H. pylori eradication. Its evidence is indication-specific rather than general: a large 2018 NEJM/PECARN trial found LGG no better than placebo for pediatric acute gastroenteritis, and a 2018 meta-analysis overturned the earlier claim that it prevents eczema. Guidelines split on it, with ESPGHAN offering a weak recommendation for acute gastroenteritis while the American Gastroenterological Association suggests against probiotics for that use. LGG is unusual in pairing genuinely strong evidence for one job with commodity pricing.

The single most studied probiotic strain on earth. The strain inside Culturelle.

What people take it for

What it is taken for. Approval, where it exists, covers only some of these.

  • Prevention of antibiotic-associated diarrhea, strongest in children (associated with reduced risk, moderate-quality evidence)
  • Prevention of antibiotic-associated diarrhea during H. pylori eradication therapy (signal, RR 0.26)
  • Adjunct in pediatric acute gastroenteritis where guidelines still permit it (weak recommendation, contested; see disputes)
  • Studied for pediatric abdominal-pain-related functional GI disorders and IBS, with a small positive meta-analysis (preliminary)
  • Studied historically for traveler's-diarrhea prevention (modest, inconsistent early signal)

What people get wrong

  • Often saidLGG fixes any gut problem

    ActuallyIts evidence is strong but indication-specific, concentrated in preventing antibiotic-associated diarrhea, particularly in children and during H. pylori eradication (Szajewska and Kolodziej 2015, 12 RCTs). It is not a general-purpose gut remedy; matching strain to indication is what matters.

  • Often saidLGG shortens or cures acute stomach flu in children

    ActuallyThe largest, most rigorous test disagrees. The 2018 NEJM/PECARN trial (971 children) found LGG no better than placebo for pediatric acute gastroenteritis, with no difference in diarrhea duration, vomiting, or missed daycare, and a parallel Canadian NEJM trial the same year was also null.

  • Often saidGiving LGG in pregnancy or infancy prevents eczema

    ActuallyThe founding 2001 Kalliomaki signal did not hold. A 2018 systematic review and meta-analysis (5 RCTs, 889 children, RR 0.90, 95% CI 0.67-1.21, high-to-moderate certainty) found no reduction in eczema risk and called for revising guidelines built on the earlier claim.

  • Often said"Most studied" means "proven for everything"

    ActuallyStudy volume is not uniform effect. The same strain that reduces antibiotic-associated diarrhea shows null results for acute gastroenteritis and eczema prevention, and non-significant results for antibiotic-associated diarrhea in adults overall. Evidence must be read outcome by outcome.

Who profits, and who pushes back

  • WHO / pediatric guidelines

    Promotes itInstitutional

    LGG is endorsed in multiple guidelines for diarrhea; among the best-evidenced strains globally.

  • Culturelle (DSM-Firmenich)

    Sells this. Has a commercial interest in a product sold as this compound, as of July 2026.

    Promotes itMass-market brand

    Sells LGG at accessible prices; a genuine, well-studied strain in a commodity product.

  • American Gastroenterological Association (AGA) guideline panel

    Pushes backUS professional-society clinical guideline (2020, Gastroenterology)

    The AGA suggests against the use of probiotics in children with acute gastroenteritis in the United States and Canada, and issued no recommendation favoring probiotics for IBS symptom response or abdominal pain, citing knowledge gaps and that many studied products are not commercially available.

  • David Schnadower, Phillip Tarr and the PECARN Probiotics Study Group

    Pushes backAuthors, 2018 NEJM randomized trial (n=971)

    Among preschool children with acute gastroenteritis, those who received a 5-day course of L. rhamnosus GG did not have better outcomes than those who received placebo.

  • Szajewska and Kolodziej (2015 AAD meta-analysis authors)

    Pushes backSystematic reviewers, Alimentary Pharmacology & Therapeutics

    LGG reduces the risk of antibiotic-associated diarrhoea, but the effect reached significance in children and in H. pylori-eradication regimens, not in adults broadly, and the overall quality of evidence is moderate to low, a scope note against over-reading the benefit.

Where the research comes from

Share of published research by country of origin.
PlaceShare of published research
USA34%
Europe32%
Asia20%
Other14%

Research published from: Global.

How we got here

The strain was isolated in 1983 from the gut of a healthy human by Sherwood Gorbach and Barry Goldin at Tufts University in Boston, who were hunting for a probiotic that could survive stomach acid and bile and adhere to the intestinal wall, properties many strains lacked. They filed a US patent in April 1985 (issued 1987); the "GG" is their initials. The Finnish dairy company Valio received the first license, and LGG spread into yogurts, juices, cheeses, and capsules across more than 40 countries, an early example of a research strain becoming a global consumer ingredient. It was deposited as ATCC 53103 and, after the 2020 Lactobacillus reclassification, is formally Lacticaseibacillus rhamnosus, though "L. rhamnosus GG" persists. Rights to the strain later consolidated under Chr. Hansen (now part of Novonesis), which licenses it to Culturelle, marketed by i-Health, a division of DSM-Firmenich. Its 2009 complete genome (Kankainen et al.) revealed the spaCBA pilus cluster carrying a human-mucus-binding protein, a molecular basis for its adhesion.

  1. 1983Gorbach and Goldin isolate the strain from a healthy human gut at Tufts
  2. 1985US patent filed (issued 1987); deposited as ATCC 53103
  3. 1990Oksanen et al. RCT of 820 Finnish tourists reports modest traveler's-diarrhea protection; Valio licenses and commercializes LGG
  4. 2001Kalliomaki et al. (Lancet) report reduced infant eczema with perinatal LGG, launching the allergy-prevention claim
  5. 2009Kankainen et al. publish the ATCC 53103 genome, describing spaCBA mucus-binding pili
  6. 2015Szajewska and Kolodziej meta-analysis (12 RCTs, 1499 participants) supports LGG for preventing antibiotic-associated diarrhea
  7. 2018Two large NEJM RCTs (Schnadower/PECARN, n=971; Freedman, Canada) find no benefit for pediatric acute gastroenteritis; a meta-analysis finds no eczema-prevention effect
  8. 2020AGA suggests against probiotics for pediatric acute gastroenteritis; Lactobacillus genus reclassified, making the strain Lacticaseibacillus rhamnosus
  9. 2022ESPGHAN position paper retains a weak recommendation for LGG in acute gastroenteritis at very low certainty

At a glance

Discovered
Gorbach & Goldin, 1985
Best for
Antibiotic diarrhea, C. diff
Brand
Culturelle
Studies
Hundreds of RCTs

What this entry does not yet cover

What follows is unfinished work on our side, not a finding about L. rhamnosus GG. A short entry is not a safe entry.

  • Cost and market. We have not documented what it sells for or who sells it.
  • Supply chain. We have not mapped where it is made.
  • Who uses it. We have not documented the user groups.
  • What could change. No forward-looking summary yet.
  • How it compares. We have not set it against the alternatives.
  • Children and teenagers. We have not checked what is known about younger people.

Sources